Avalo Therapeutics (AVTX) Stock Forecast, Price Target & Predictions
AVTX Stock Forecast
Avalo Therapeutics stock forecast is as follows: an average price target of $35.00 (represents a 262.69% upside from AVTX’s last price of $9.65) and a rating consensus of 'Hold', based on 4 wall street analysts offering a 1-year stock forecast.
AVTX Price Target
AVTX Analyst Ratings
Hold
Avalo Therapeutics Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Apr 16, 2024 | Leland Gershell | Oppenheimer | $35.00 | $15.24 | 129.66% | 262.69% |
10
Avalo Therapeutics Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | 1 |
Avg Price Target | - | - | $35.00 |
Last Closing Price | $9.65 | $9.65 | $9.65 |
Upside/Downside | -100.00% | -100.00% | 262.69% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Oct 24, 2024 | H.C. Wainwright | - | Neutral | Initialise |
Aug 15, 2024 | Oppenheimer | Outperform | Outperform | Hold |
Apr 16, 2024 | Oppenheimer | - | Outperform | Upgrade |
Jun 27, 2023 | Stephens | Equal-Weight | Equal-Weight | Hold |
Jun 27, 2023 | RBC Capital | - | Sector Perform | Downgrade |
Feb 08, 2023 | Jefferies | - | Underperform | Downgrade |
10
Avalo Therapeutics Financial Forecast
Avalo Therapeutics Revenue Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 17 | Jun 16 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | $236.00K | $643.00K | $475.00K | $896.00K | $14.95M | $1.03M | $1.17M | $219.00K | $1.35M | $3.35M | $473.00K | $1.11M | $1.34M | $2.75M | $-8.72M | $5.61M | $4.45M | $5.41M | $384.21K | $650.49K |
Avg Forecast | $241.62K | $243.07K | $244.54K | $246.02K | $300.00K | $300.00K | $300.00K | $300.00K | $300.00K | $1.00M | $1.00M | $1.00M | $3.61M | $1.26M | $1.19M | $645.50K | $1.02M | $1.12M | $333.33K | $539.33K | $1.50M | $2.25M | $1.84M | $4.95M | $5.34M | $4.71M | $3.17M | $748.19K | $698.08K |
High Forecast | $241.62K | $243.07K | $244.54K | $246.02K | $300.00K | $300.00K | $300.00K | $300.00K | $300.00K | $1.00M | $1.00M | $1.00M | $3.61M | $1.26M | $1.19M | $645.50K | $1.02M | $1.12M | $333.33K | $539.33K | $1.50M | $2.25M | $1.84M | $4.95M | $5.34M | $4.71M | $3.81M | $897.83K | $837.70K |
Low Forecast | $241.62K | $243.07K | $244.54K | $246.02K | $300.00K | $300.00K | $300.00K | $300.00K | $300.00K | $1.00M | $1.00M | $1.00M | $3.61M | $1.26M | $1.19M | $645.50K | $1.02M | $1.12M | $333.33K | $539.33K | $1.50M | $2.25M | $1.84M | $4.95M | $5.34M | $4.71M | $2.54M | $598.55K | $558.47K |
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 15 | 16 | 8 | 11 | 7 | 11 | 7 | 17 | 15 | 12 |
Surprise % | - | - | - | - | - | - | - | - | - | 0.24% | 0.64% | 0.47% | 0.25% | 11.88% | 0.87% | 1.82% | 0.22% | 1.21% | 10.07% | 0.88% | 0.74% | 0.59% | 1.49% | -1.76% | 1.05% | 0.95% | 1.71% | 0.51% | 0.93% |
Forecast
Avalo Therapeutics EBITDA Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 17 | Jun 16 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 15 | 16 | 8 | 11 | 7 | 11 | 7 | 17 | 15 | 12 |
EBITDA | - | - | - | - | - | - | - | - | - | $-3.75M | $-7.15M | $-8.82M | $-8.82M | $4.09M | $-11.80M | $-20.79M | $-20.10M | $-15.95M | $-17.09M | $-30.20M | $-13.03M | $-13.30M | $-22.81M | $2.91M | $-3.04M | $-5.25M | $-6.40M | $-2.01M | $-3.64M |
Avg Forecast | $-241.62K | $-243.07K | $-244.54K | $-246.02K | $-300.00K | $-300.00K | $-300.00K | $-300.00K | $-300.00K | $-1.00M | $-1.00M | $-1.00M | $-3.61M | $-1.26M | $-1.19M | $-11.75M | $-1.02M | $-1.12M | $-333.33K | $-21.77M | $-1.50M | $-2.25M | $-31.95M | $-4.95M | $-5.34M | $-4.71M | $-7.35M | $-2.62M | $-3.76M |
High Forecast | $-241.62K | $-243.07K | $-244.54K | $-246.02K | $-300.00K | $-300.00K | $-300.00K | $-300.00K | $-300.00K | $-1.00M | $-1.00M | $-1.00M | $-3.61M | $-1.26M | $-1.19M | $-9.40M | $-1.02M | $-1.12M | $-333.33K | $-17.42M | $-1.50M | $-2.25M | $-25.56M | $-4.95M | $-5.34M | $-4.71M | $-5.88M | $-2.09M | $-3.01M |
Low Forecast | $-241.62K | $-243.07K | $-244.54K | $-246.02K | $-300.00K | $-300.00K | $-300.00K | $-300.00K | $-300.00K | $-1.00M | $-1.00M | $-1.00M | $-3.61M | $-1.26M | $-1.19M | $-14.10M | $-1.02M | $-1.12M | $-333.33K | $-26.13M | $-1.50M | $-2.25M | $-38.34M | $-4.95M | $-5.34M | $-4.71M | $-8.82M | $-3.14M | $-4.51M |
Surprise % | - | - | - | - | - | - | - | - | - | 3.75% | 7.15% | 8.82% | 2.44% | -3.25% | 9.94% | 1.77% | 19.75% | 14.29% | 51.26% | 1.39% | 8.69% | 5.91% | 0.71% | -0.59% | 0.57% | 1.12% | 0.87% | 0.77% | 0.97% |
Forecast
Avalo Therapeutics Net Income Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 17 | Jun 16 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 15 | 16 | 8 | 11 | 7 | 11 | 7 | 17 | 15 | 12 |
Net Income | - | - | - | - | - | - | - | - | - | $-5.23M | - | $-9.96M | $-9.81M | $3.19M | $-12.99M | $-22.05M | $-19.13M | $-17.39M | $-17.11M | $-30.68M | $-13.46M | $-13.28M | $-21.12M | $1.62M | $-4.02M | $-6.22M | $-7.45M | $-1.96M | $-3.52M |
Avg Forecast | $-12.19M | $-12.40M | $-11.97M | $-12.19M | $-12.02M | $-12.83M | $-72.25M | $-12.73M | $-51.76M | $-2.85B | $-2.07B | $-2.51B | $-1.90B | $-1.61B | $-3.25B | $-11.20M | $-3.26B | $-3.70B | $-3.67B | $-22.11M | $-2.09B | $-2.31B | $-29.56M | $-2.57B | $-3.09B | $-3.23B | $-8.85M | $-2.62M | $-3.76M |
High Forecast | $-12.19M | $-12.40M | $-11.97M | $-12.19M | $-11.70M | $-12.83M | $-72.25M | $-12.73M | $-51.76M | $-2.85B | $-2.07B | $-2.51B | $-1.90B | $-1.61B | $-3.25B | $-8.96M | $-3.26B | $-3.70B | $-3.67B | $-17.68M | $-2.09B | $-2.31B | $-23.65M | $-2.57B | $-3.09B | $-3.23B | $-7.08M | $-2.10M | $-3.01M |
Low Forecast | $-12.19M | $-12.40M | $-11.97M | $-12.19M | $-12.24M | $-12.83M | $-72.25M | $-12.73M | $-51.76M | $-2.85B | $-2.07B | $-2.51B | $-1.90B | $-1.61B | $-3.25B | $-13.43M | $-3.26B | $-3.70B | $-3.67B | $-26.53M | $-2.09B | $-2.31B | $-35.48M | $-2.57B | $-3.09B | $-3.23B | $-10.62M | $-3.15M | $-4.52M |
Surprise % | - | - | - | - | - | - | - | - | - | 0.00% | - | 0.00% | 0.01% | -0.00% | 0.00% | 1.97% | 0.01% | 0.00% | 0.00% | 1.39% | 0.01% | 0.01% | 0.71% | -0.00% | 0.00% | 0.00% | 0.84% | 0.75% | 0.94% |
Forecast
Avalo Therapeutics SG&A Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 17 | Jun 16 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 15 | 16 | 8 | 11 | 7 | 11 | 7 | 17 | 15 | 12 |
SG&A | - | - | - | - | - | - | - | - | - | $2.49M | $2.43M | $2.71M | $2.96M | $3.28M | $2.78M | $11.68M | $5.98M | $5.93M | $7.40M | $5.35M | $5.04M | $6.75M | $3.35M | $-4.85M | $5.31M | $5.32M | $5.83M | $1.33M | $1.64M |
Avg Forecast | $760.51K | $765.10K | $769.72K | $774.37K | $944.28K | $944.28K | $944.28K | $944.28K | $944.28K | $3.15M | $3.15M | $3.15M | $11.36M | $3.96M | $3.73M | $2.03M | $3.20M | $3.51M | $1.05M | $1.70M | $4.72M | $7.08M | $5.80M | $15.58M | $16.79M | $14.82M | $9.98M | $2.36M | $2.20M |
High Forecast | $760.51K | $765.10K | $769.72K | $774.37K | $944.28K | $944.28K | $944.28K | $944.28K | $944.28K | $3.15M | $3.15M | $3.15M | $11.36M | $3.96M | $3.73M | $2.03M | $3.20M | $3.51M | $1.05M | $1.70M | $4.72M | $7.08M | $5.80M | $15.58M | $16.79M | $14.82M | $11.98M | $2.83M | $2.64M |
Low Forecast | $760.51K | $765.10K | $769.72K | $774.37K | $944.28K | $944.28K | $944.28K | $944.28K | $944.28K | $3.15M | $3.15M | $3.15M | $11.36M | $3.96M | $3.73M | $2.03M | $3.20M | $3.51M | $1.05M | $1.70M | $4.72M | $7.08M | $5.80M | $15.58M | $16.79M | $14.82M | $7.98M | $1.88M | $1.76M |
Surprise % | - | - | - | - | - | - | - | - | - | 0.79% | 0.77% | 0.86% | 0.26% | 0.83% | 0.75% | 5.75% | 1.87% | 1.69% | 7.06% | 3.15% | 1.07% | 0.95% | 0.58% | -0.31% | 0.32% | 0.36% | 0.58% | 0.56% | 0.74% |
Forecast
Avalo Therapeutics EPS Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 17 | Jun 16 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 15 | 16 | 8 | 11 | 7 | 11 | 7 | 17 | 15 | 12 |
EPS | - | - | - | - | - | - | - | - | - | $-0.11 | $-0.59 | $-0.85 | $-1.16 | $0.34 | $-1.38 | $-2.35 | $-2.28 | $-2.04 | $-2.16 | $-3.84 | $-2.04 | $-2.28 | $-4.08 | $0.35 | $-0.84 | $-1.32 | $-1.56 | $-2.28 | $-4.92 |
Avg Forecast | $-1.13 | $-1.15 | $-1.11 | $-1.13 | $-1.11 | $-1.19 | $-6.70 | $-1.18 | $-4.80 | $-264.00 | $-192.00 | $-232.80 | $-176.00 | $-210.60 | $-424.80 | $-360.00 | $-426.24 | $-483.84 | $-480.00 | $-480.00 | $-273.60 | $-302.40 | $-297.60 | $-336.00 | $-403.20 | $-422.40 | $-2.28 | $-5.94 | $-5.64 |
High Forecast | $-1.13 | $-1.15 | $-1.11 | $-1.13 | $-1.09 | $-1.19 | $-6.70 | $-1.18 | $-4.80 | $-264.00 | $-192.00 | $-232.80 | $-176.00 | $-210.60 | $-424.80 | $-360.00 | $-426.24 | $-483.84 | $-480.00 | $-480.00 | $-273.60 | $-302.40 | $-297.60 | $-336.00 | $-403.20 | $-422.40 | $-1.82 | $-4.75 | $-4.51 |
Low Forecast | $-1.13 | $-1.15 | $-1.11 | $-1.13 | $-1.13 | $-1.19 | $-6.70 | $-1.18 | $-4.80 | $-264.00 | $-192.00 | $-232.80 | $-176.00 | $-210.60 | $-424.80 | $-360.00 | $-426.24 | $-483.84 | $-480.00 | $-480.00 | $-273.60 | $-302.40 | $-297.60 | $-336.00 | $-403.20 | $-422.40 | $-2.74 | $-7.13 | $-6.77 |
Surprise % | - | - | - | - | - | - | - | - | - | 0.00% | 0.00% | 0.00% | 0.01% | -0.00% | 0.00% | 0.01% | 0.01% | 0.00% | 0.00% | 0.01% | 0.01% | 0.01% | 0.01% | -0.00% | 0.00% | 0.00% | 0.68% | 0.38% | 0.87% |
Forecast
Avalo Therapeutics Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
BNOX | Bionomics | $0.28 | $6.00 | 2042.86% | Buy |
ALXO | ALX Oncology | $1.29 | $24.50 | 1799.22% | Buy |
IPSC | Century Therapeutics | $1.24 | $15.00 | 1109.68% | Buy |
PMVP | PMV Pharmaceuticals | $1.61 | $18.00 | 1018.01% | Buy |
MOLN | Molecular Partners | $5.42 | $29.00 | 435.06% | Buy |
AVTE | Aerovate Therapeutics | $2.61 | $13.00 | 398.08% | Hold |
ANEB | Anebulo Pharmaceuticals | $1.50 | $6.00 | 300.00% | Buy |
AVTX | Avalo Therapeutics | $9.65 | $35.00 | 262.69% | Hold |
ACRV | Acrivon Therapeutics | $6.44 | $21.83 | 238.98% | Buy |
CCCC | C4 Therapeutics | $4.01 | $13.50 | 236.66% | Buy |
GPCR | Structure Therapeutics | $30.10 | $92.40 | 206.98% | Buy |
CGEM | Cullinan Oncology | $12.22 | $31.50 | 157.77% | Buy |
MLYS | Mineralys Therapeutics | $11.87 | $30.00 | 152.74% | Buy |
ANAB | AnaptysBio | $21.17 | $52.00 | 145.63% | Buy |
BNTC | Benitec Biopharma | $10.20 | $20.33 | 99.31% | Buy |
EWTX | Edgewise Therapeutics | $31.98 | $45.00 | 40.71% | Buy |
ACLX | Arcellx | $87.22 | $83.00 | -4.84% | Buy |